Cargando…
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP
PURPOSE: The Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007 and updated in 2021 (STEEP 2.0), provide standardized definitions of adjuvant breast cancer (BC) end points. STEEP 2.0 identified a need to separately address end points for neoadjuvant clinical trial...
Autores principales: | Litton, Jennifer K., Regan, Meredith M., Pusztai, Lajos, Rugo, Hope S., Tolaney, Sara M., Garrett-Mayer, Elizabeth, Amiri-Kordestani, Laleh, Basho, Reva K., Best, Ana F., Boileau, Jean-Francois, Denkert, Carsten, Foster, Jared C., Harbeck, Nadia, Jacene, Heather A., King, Tari A., Mason, Ginny, O'Sullivan, Ciara C., Prowell, Tatiana M., Richardson, Andrea L., Sepulveda, Karla A., Smith, Mary Lou, Tjoe, Judy A., Turashvili, Gulisa, Woodward, Wendy A., Butler, Lynn Pearson, Schwartz, Elena I., Korde, Larissa A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522109/ https://www.ncbi.nlm.nih.gov/pubmed/37433103 http://dx.doi.org/10.1200/JCO.23.00435 |
Ejemplares similares
-
ADNP (Activity Dependent Neuroprotector Homeobox): A novel oncogene driving poor prognosis in high-grade serous carcinoma
por: Turashvili, Gulisa
Publicado: (2020) -
Tumor Heterogeneity in Breast Cancer
por: Turashvili, Gulisa, et al.
Publicado: (2017) -
Pathology of Hereditary Breast and Ovarian Cancer
por: Hodgson, Anjelica, et al.
Publicado: (2020) -
What’s new in gynecologic pathology 2021: ovary and fallopian tube
por: Turashvili, Gulisa, et al.
Publicado: (2021) -
Are Columnar Cell Lesions the Earliest Non-Obligate Precursor in the Low-Grade Breast Neoplasia Pathway?
por: Strickland, Sarah, et al.
Publicado: (2022)